Mucosally-targeted HIV-1 vaccines

Human Vaccines

Volumn 7, Issue 9, 2011, Pages 982-985

  Wegmann, Frank ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIV 1 vaccine; Intranasal immunization; Mucosal immunity; Vaginal IgA; Vaginal immunization

Indexed keywords

ADJUVANT; ALUMINUM SALT; ANTIRETROVIRUS AGENT; CHOLERA TOXIN B SUBUNIT; CPG OLIGODEOXYNUCLEOTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LABILE TOXIN; LTK 63; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIGEN; TOXIN; UNCLASSIFIED DRUG;

AFRICA SOUTH OF THE SAHARA; ANTIGEN PURIFICATION; BEHAVIOR CHANGE; BELL PALSY; CIRCUMCISION; DRUG DELIVERY SYSTEM; DRUG TARGETING; EPIDEMIC; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; MUCOSA; MUCOSAL ADMINISTRATION; MUCOSAL IMMUNITY; NONHUMAN; NOTE; PATIENT EDUCATION; POLYOMAVIRUS INFECTION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; MUCOUS MEMBRANE;

EID: 80053541359     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.9.16505     Document Type: Note

References (40)

1. Brandtzaeg P. Mucosal immunity in the female genital tract. J Reprod Immunol 1997; 36:23-50; PMID:9430737; DOI:10.1016/S0165-0378(97)00061-2.
2. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84:1302-13; PMID:19906907; DOI:10.1128/JVI.01272-09.
3. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-10; PMID:10655111; DOI:10.1038/72318.
4. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189:2167-73; PMID:15181562; DOI:10.1086/420833.
5. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:1000433; PMID:19436712; DOI:10.1371/journal.ppat.1000433.
6. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007; 25:5467-84; PMID:17227687; DOI:10.1016/j.vaccine.2006. 12.001.
7. Ghys PD, Belec L, Diallo MO, Ettiegne-Traore V, Becquart P, Maurice C, et al. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d'Ivoire. AIDS 2000; 14:2603-8; PMID:11101074; DOI:10.1097/00002030-200011100-00025.
8. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997; 3:1250-7; PMID:9359700; DOI:10.1038/nm1197-1250.
9. Nguyen M, Pean P, Lopalco L, Nouhin J, Phoung V, Ly N, et al. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr 2006; 42:412-9; PMID:16837821; DOI:10.1097/01.qai.0000222289. 97825.35.
10. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2:412-26; PMID:19587640; DOI:10.1038/mi.2009.89.
11. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. Immunity 2011; 34:269-80; PMID:21315623; DOI:10.1016/j.immuni.2011.01.015.
12. Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, Hage A, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009; 323:1726-9; PMID:19325114; DOI:10.1126/science.1168676.
13. Iijima N, Linehan MM, Zamora M, Butkus D, Dunn R, Kehry MR, et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med 2008; 205:3041-52; PMID:19047439; DOI:10.1084/jem. 20082039.
14. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-92; PMID:19648930; DOI:10.1038/nm.2006.
15. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204:595-603; PMID:17325200; DOI:10.1084/jem.20061792.
16. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11:63-8; PMID:15812492; DOI:10.1038/nm1210.
17. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; PMID:17931153; DOI:10.1586/14760584.6.5.723.
18. DeFrancesco L. Dynavax trial halted. Nat Biotechnol 2008; 26:484; PMID:18464766; DOI:10.1038/nbt0508-484a.
19. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009; 21:23-9; PMID:19246182; DOI:10.1016/j.coi.2009.01.004.
20. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314:1936-8; PMID:17185603; DOI:10.1126/science.1135299.
21. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland. N Engl J Med 2004; 350:896-903; PMID:14985487; DOI:10.1056/ NEJMoa030595.
22. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009; 4:6999; PMID:19756141; DOI:10.1371/journal.pone.0006999.
23. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9; PMID:17006278; DOI:10.1097/01.inf.0000237797.14283.cf.
24. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-7; PMID:21350488; DOI:10.1038/nature09737.
25. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The utility of ADCC responses in HIV infection. Curr HIV Res 2008; 6:515-9; PMID:18991616; DOI:10.2174/157016208786501472.
26. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3:42-7; PMID:8986739; DOI:10.1038/nm0197-42.
27. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003; 3:822-9; PMID:14523388; DOI:10.1038/nri1203.
28. Zinckgraf JW, Winchell JM, Silbart LK. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide. J Reprod Immunol 1999; 45:99-112; PMID:10674979; DOI:10.1016/S0165-0378(99)00042-X.
29. Johansson EL, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 1998; 66:514-20; PMID:9453604.
30. Imaoka K, Miller CJ, Kubota M, McChesney MB, Lohman B, Yamamoto M, et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998; 161:5952-8; PMID:9834076.
31. Bergquist C, Johansson EL, Lagergaärd T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997; 65:2676-84; PMID:9199436.
32. Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YY, Holmgren J, et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009; 183:7851-9; PMID:19933861; DOI:10.4049/jimmunol.0803740.
33. Black CA, Rohan LC, Cost M, Watkins SC, Draviam R, Alber S, et al. Vaginal mucosa serves as an inductive site for tolerance. J Immunol 2000; 165:5077-83; PMID:11046038.
34. Curran RM, Donnelly L, Morrow RJ, Fraser C, Andrews G, Cranage M, et al. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 2009; 27:6791-8; PMID:19747994; DOI:10.1016/j.vaccine.2009.08.088.
35. Lee JB, Jang JE, Song MK, Chang J. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS ONE 2009; 4:5190; PMID:19360100; DOI:10.1371/journal.pone.0005190.
36. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 2004; 190:1841-9; PMID:15499542; DOI:10.1086/425079.
37. Nurkkala M, Nordstrom I, Telemo E, Eriksson K. MHC expression and chemokine production in the murine vagina following intra-vaginal administration of ligands to toll-like receptors 3, 7 and 9. J Reprod Immunol 2007; 73:148-57; PMID:17081619; DOI:10.1016/j.jri.2006.09.001.
38. Wegmann F, Krashias G, Luhn K, Laamanen K, Vieira S, Jeffs SA, et al. A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. PLoS ONE 2011; 6:15861; PMID:21253014; DOI:10.1371/journal.pone.0015861.
39. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74; PMID:20643915; DOI:10.1126/science.1193748.
40. Sattentau QJ, McMichael AJ. New templates for HIV-1 antibody-based vaccine design. F1000 Biol Rep 2010; 2:60; PMID:21173880.